Inhibition of proteases during extracorporeal extremity perfusion experimental and clinical results.
In an experimental and clinical study a significant reduction of the postoperative edema after extracorporeal extremity perfusion under addition of Aprotinin was observed. Together with reduction of edema usually expected complications like pain and peripheral nerve damage could be reduced significantly. Preliminary, yet unpublished data on cytostatic infusion of the pancreas also indicate that intraarterial Aprotinin when given simultaneously may prevent pancreatitis. It is mandatory Aprotinin to be given early enough in sufficiently high dose and there seems to be an advantage when the arterial route is used.
Walther
H
H
Department of General and Oncologic Surgery, Trosberg Hospital.
Müller
H
H
Aigner
K R
KR
D000818:Animals; D007611:Aprotinin / Q000378:metabolism; D010478:Chemotherapy, Cancer, Regional Perfusion; D002986:Clinical Trials as Topic; D003402:Creatine Kinase / Q000032:analysis; D004285:Dogs; D005121:Extremities; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000378:metabolism*; D011897:Random Allocation; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014751:Vindesine / Q000494:pharmacology
D011480:Protease Inhibitors; D007611:Aprotinin; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D014751:Vindesine